Small Molecules
13 September 2016
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes13 September 2016
Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea13 September 2016
Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis13 September 2016
RespireRx Pharmaceuticals Inc. Announces Preliminary Top-Line Analysis of Data From Duke University Phase 2A Clinical Trial of CX173912 September 2016
Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin12 September 2016
Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency12 September 2016
Sunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-06212 September 2016
US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer12 September 2016
Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate10 September 2016
Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes9 September 2016
GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer9 September 2016
Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 20169 September 2016
Cytokinetics Announces Next-Generation Fast Skeletal Muscle Activator Entering IND-Enabling Studies9 September 2016
RedHill Biopharma Announces Phase Ib/II Study with YELIVA™ Initiated for Multiple Myeloma at a Leading U.S. Academic Medical Center8 September 2016
Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation8 September 2016
Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK7 September 2016
Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease7 September 2016
BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model7 September 2016
Sage Receives FDA Breakthrough Therapy Designation for SAGE-547 for the Treatment of Postpartum Depression7 September 2016
Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking CessationNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports